Khanna D, et al. - The efficacy and safety of tocilizumab were evaluated in patients with systemic sclerosis (SSc) in a phase II study. Researchers observed skin score improvement and forced vital capacity stabilization in the double-blind period in placebo-treated patients who transitioned to tocilizumab. These were maintained in the open-label period. In patients with SSc, safety data showed increased serious infections, but no new safety signals with tocilizumab.